Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
7.24
-0.47 (-6.10%)
At close: Dec 5, 2025, 4:00 PM EST
7.14
-0.10 (-1.38%)
After-hours: Dec 5, 2025, 7:37 PM EST

Moleculin Biotech Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Net Income
-51.41-21.76-29.77-29.03-15.89-17.36
Upgrade
Depreciation & Amortization
0.110.130.130.130.160.2
Upgrade
Loss (Gain) From Sale of Assets
-----0.01
Upgrade
Stock-Based Compensation
1.631.731.982.282.371.68
Upgrade
Other Operating Activities
27.49-4.182.45-1.24-6.63-2.26
Upgrade
Change in Accounts Payable
-0.48-0.470.40.730.24-1.02
Upgrade
Change in Other Net Operating Assets
0.20.71.22-0.510.80.98
Upgrade
Operating Cash Flow
-22.45-23.86-23.59-27.64-18.95-17.77
Upgrade
Capital Expenditures
--0.01-0.12-0.07-0.02-0.38
Upgrade
Sale of Property, Plant & Equipment
-----0
Upgrade
Investing Cash Flow
--0.01-0.12-0.07-0.02-0.37
Upgrade
Issuance of Common Stock
19.84.664.17-74.7522.57
Upgrade
Repurchase of Common Stock
--0.03-0.03-0.02-0.02-0.02
Upgrade
Financing Cash Flow
19.84.644.14-0.0274.7222.55
Upgrade
Foreign Exchange Rate Adjustments
-0.05-0.03-0.02-0.03-0.020.03
Upgrade
Net Cash Flow
-2.7-19.27-19.6-27.7655.734.44
Upgrade
Free Cash Flow
-22.45-23.88-23.72-27.71-18.97-18.15
Upgrade
Free Cash Flow Per Share
-33.25-173.36-300.10-363.22-264.69-691.18
Upgrade
Cash Income Tax Paid
-----0.02
Upgrade
Levered Free Cash Flow
-12.18-14.36-14.6-16.09-10.17-10.77
Upgrade
Unlevered Free Cash Flow
-12.18-14.36-14.6-16.09-10.17-10.77
Upgrade
Change in Working Capital
-0.280.231.620.221.04-0.04
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.